根据一份向美国证券交易委员会提交的文件,生物制药公司Plus Therapeutics, Inc. 已签订一项股权分销协议。该协议涉及公司可通过销售其普通股筹集高达1735万美元的资金。
此项安排为Plus Therapeutics提供了一种灵活的融资机制,使其能够在未来根据市场条件和公司需求,通过指定的销售代理逐步出售股票。
根据一份向美国证券交易委员会提交的文件,生物制药公司Plus Therapeutics, Inc. 已签订一项股权分销协议。该协议涉及公司可通过销售其普通股筹集高达1735万美元的资金。
此项安排为Plus Therapeutics提供了一种灵活的融资机制,使其能够在未来根据市场条件和公司需求,通过指定的销售代理逐步出售股票。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.